ScreenerHero

CPH Cipher Pharmaceuticals Inc.

TSX · CA · Healthcare · Drug Manufacturers - Specialty & Generic · cipherpharma.com
13.70CAD+0.37%Mkt Cap: 253.57M $P/E: 8.95

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and r…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited
$56.90BUSD
TEVA
Teva Pharmaceutical Industries Limited
$46.26BUSDP/E 66.1
HLN
Haleon plc
$38.79BUSDP/E 18.0
ZTS
Zoetis Inc.
$29.51BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
UTHR
United Therapeutics Corporation
$23.01BUSDP/E 19.2
VTRS
Viatris Inc.
$20.24BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc.
$14.66BUSDP/E 21.1
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.25BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.26BUSDP/E 28.0
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
ALKS
Alkermes plc
$7.17BUSDP/E 112.5
AMRX
Amneal Pharmaceuticals, Inc.
$7.09BUSDP/E 41.5
HIMS
Hims & Hers Health, Inc.
$6.92BUSD
LNTH
Lantheus Holdings, Inc.
$6.54BUSDP/E 24.3
KNSA
Kiniksa Pharmaceuticals International, plc
$5.87BUSDP/E 77.1
APTX
Apotex Health Corp.
$5.17BUSD

Key Statistics

Company
Market Cap253.57M USD
Enterprise Value246.28M USD
Revenue (TTM)36.14M USD
Gross Profit29.44M USD
Net Income (TTM)19.90M USD
Revenue/Share1.96 CAD
Last Price13.70 CAD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)8.95
P/E (Forward)11.97
PEG—
EV/EBITDA12.77
EV/Revenue6.81
P/S6.99
P/B1.77
EPS (TTM)1.53
EPS (Forward)1.14
52W Range
12.4815% of range20.56
52W High20.56 CAD
52W Low12.48 CAD
Profitability
Gross Margin80.12%
Oper. Margin39.23%
EBITDA Margin53.36%
Profit Margin54.17%
ROE21.65%
ROA17.46%
Growth
Revenue Growth-9.80%
Earnings Growth-31.80%
Cash Flow & Leverage
Operating CF21.65M USD
CapEx (TTM)146.38K USD
FCF Margin38.72%
FCF Yield5.52%
Net Debt-6.37M USD
Net Debt/EBITDA-0.33
Balance Sheet
Debt/Equity0.04
Current Ratio1.59
Quick Ratio1.09
Book Value/Sh7.69 CAD
Cash/Share0.36 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 CAD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)19.45 CAD
Upside (mean)+42.0%
Target Range17.00 CAD – 21.30 CAD
17.00+42.0% to mean21.30
# Analysts4
Ownership
Shares Out.25.42M
Float14.82M
Insiders42.54%
Institutions1.28%
Short Interest
Short Ratio0.9d
Short % Out.0.14%
Shares Short34.90K
Short (prev mo.)71.78K
Technical
SMA 5014.90 (-8.0%)
SMA 20015.97 (-14.2%)
Beta0.40
S&P 52W Chg14.58%
Avg Vol (30d)38.95K
Avg Vol (10d)22.00K
Technical Indicators
RSI (14)34.9
MACD-0.3943
MACD Signal-0.3982
MACD Hist.+0.0039
BB Upper14.89 CAD
BB Middle14.14 CAD
BB Lower13.39 CAD
BB Width10.57%
ATR (14)0.3618 CAD
Vol Ratio (20d)1.09x